Equity

6 Months Ended

Jun. 30, 2011

Equity

Equity

12. Equity

Changes in equity for the six months ended June 30, 2011 were as follows (in thousands, except share amounts):

	Gentiva Shareholders
					Additional Paid-in Capital			Retained Earnings		Accumulated Other Comprehensive Income (Loss)			Treasury Stock			Noncontrolling Interests			Total
	Common Stock
	Shares		Amount
Balance at December 31, 2010		30,799,091	$	3,080	$	372,106		$	272,394	$	478		$	(12,484	)	$	2,658		$	638,232
Comprehensive income:
Net income		—		—		—			18,641		—			—			318			18,959
Unrealized loss on interest rate swap		—		—		—			—		(768	)		—			—			(768	)
Realized loss on interest rate swap		—		—		—			—		290			—			—			290
Total comprehensive income		—		—		—			18,641		(478	)		—			318			18,481
Income tax benefits associated with the exercise of non-qualified stock options		—		—		259			—		—			—			—			259
Equity-based compensation expense		—		11		4,361			—		—			—			—			4,372
Issuance of stock upon exercise of stock options and under stock plans for employees and directors		420,593		31		6,204			—		—			—			—			6,235
Purchase of non-controlling interest		—		—		(352	)		—		—			—			32			(320	)
Distribution to partnership interests		—		—		—			—		—			—			(478	)		(478	)
Treasury shares:
Common stock received from Healthfield escrow (14,334 shares)		—		—		—			—		—			(394	)		—			(394	)
Balance at June 30, 2011		31,219,684	$	3,122	$	382,578		$	291,035	$	—		$	(12,878	)	$	2,530		$	666,387

Comprehensive income amounted to $5.3 million and $18.5 million for the second quarter and first six months of 2011, respectively, and $18.9 million and $28.2 million for the second quarter and first six months of fiscal 2010, respectively. During the second quarter of 2011, the Company purchased the noncontrolling interest in one of the Company's hospice programs for $0.3 million.

The Company has an authorized stock repurchase program under which the Company can repurchase and retire up to 1,500,000 shares of its outstanding common stock. The repurchases can occur periodically in the open market or through privately negotiated transactions based on market conditions and other factors. During the six months ended June 30, 2011, the Company did not repurchase shares of its outstanding common stock. As of June 30, 2011, the Company had remaining authorization to repurchase an aggregate of 180,568 shares of its outstanding common stock. The Company's Credit Agreement and the indenture governing the Senior Notes provide for repurchases of the Company's common stock not to exceed $5.0 million per year, and not to exceed $10.0 million per year if the consolidated leverage ratio is less than or equal to 3.5:1 immediately after giving effect on a pro forma basis to the repurchase.